RegMed Investors’ (RMi) pre-open: I’d be “picking up sticks” some sector stocks

June 16, 2025 8:11am

After 4 negative session closings, when there are bombs dropping and chaos in the streets, how horrible yet bottoms are attractive especially with M&A in the offing and clinical news

Review the week’s volatility, VIX: Friday 20.82, from 18.02, Wednesday’s 17.72, from 17.27, Monday’s 16.86 and the previous Friday’s 17.16

NEWS: Supernus Pharmaceuticals (SUPN -$0.70) to acquire Sage Therapeutics (SAGE +$2.30 or +34.33% to $9.00 after closing at $6.70), Upfront cash payment of $8.50 per share, plus 1-non-tradable contingent value right (CVR) payable upon achieving certain specific milestones collectively worth up to $3.50 per share in cash, for an aggregate of up to approximately $795 M or $12.00 per share.

Intellia Therapeutics (NTLA +$0.20 or +2.41% to $8.51 after close at $8.31) Positive 3-Year Data from P1 Trial (10 patient) of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE). All 10 patients were attack-free and treatment-free for a median of 23 months through the latest follow-up, demonstrating the potential of lonvo-z to become the first one-time therapy for most HAE patients

No false narratives or fake news; to read insights and analysis on the latest sector action, check out Pre-Open Brief

Never leave an investor uninformed!

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

“I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened to make “it” happen today!

Friday’s night’s … RegMed Investors (RMi) Closing Bell: sector bottoms evident as collateral damage… https://www.regmedinvestors.com/articles/13960

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB): PONZI Scheme at its best or was convicted Bernie Madoff also resurrected … https://www.regmedinvestors.com/articles/13812

Monday: The pre-open Dow futures are UP +0.58% or (+245 points), the S&P futures are UP +0.65% or (+39 points) and the Nasdaq futures are UP +0.80% or (+174 points)

• Stock futures rebounded slightly early Monday 5/16 amid rising geopolitical risk,
• European markets rebounded,
• Asia-Pacific markets rose.

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

• Last week dragged the major averages into negative territory on the week. The S&P 500 lost -0.4%, while the Nasdaq slid -0.6% and the Dow fell 1.3%.

Last week:

• Friday: The Dow closed DOWN -769.83 points or -1.79%, the S&P closed DOWN -68.29 points or -1.13% while the Nasdaq closed DOWN -255.66 points or -1.30%
• Thursday: The Dow closed UP +101.85 points or +0.24%, the S&P closed UP +23.02 points or +0.38% while the Nasdaq closed UP +46.61 points or +0.24%
• Wednesday: The Dow closed DOWN -1.10 points or -0.00%, the S&P closed DOWN -16.51 points or -0.27% while the Nasdaq closed DOWN -99.10 points or -0.50%
• Tuesday: The Dow closed UP +105.11 points or +0.25%, the S&P closed UP +32.93 points or +0.55% while the Nasdaq closed UP +123.75 points or +0.63%
• Monday: The Dow closed DOWN -1.11 points or -0.00%, the S&P closed UP +5.52 points or +0.09% while the Nasdaq closed UP +61.28 points or +0.30%

Economic Data Docket:  Empire State manufacturing survey

Q2 – June – 3 negative, 1 neutral and 6 positive closes

• May – 1 market holiday, 10 negative and 11 positive closes
• Q2 - April – 10 negative and 11 positive closes

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

• Better part of valor to not lead any investor to temptation; yet again, I am forecasting the daily indications as to expectation and the pre-open waits for the …  impact of another M&A and some clinical data, it is ...still a mix of ups, downs and just uncertainty

The BOTTOM LINE: The market along with the cell and gene therapy sector hasn’t changed the same old risk positioning; until then, it remains a tactical investment decision offering a good excuse for traders to take profits on uprises and reassess entry positions i.e. buys.

Also, “Investors are heading into the coming week’s 2-day Fed meeting facing a wide band of uncertainty around the path ahead for the U.S. economy, inflation, and interest rates — which has the potential to keep stocks rangebound, make them more volatile, or both through the end of the year.” <MarketWatch>

Not a clairvoyant, there are geopolitical tensions that cause sessions that are just a flip-of-the-coin

June ’25: understand the “flow” of markets, the cell and gene therapy sector and economic karma…

• 6/13 - Friday closed negative with 5 positive, 25 negative and 5 flats
• 6/12 – Thursday closed negative with 7 positive, 23 negative and 5 flats
• 6/11 – Wednesday closed negative with 6 positive, 25 negative and 4 flats
• 6/10 - Tuesday closed positive with 17 positive, 15 negative and 3 flats
• 6/9 - Monday closed neutral with 16 positive, 16 negative and 3 flats
• 6/6 – Friday negative with 4 positive, 28 negative and 3 flats
• 6/5 - Thursday closed positive with 16 positive, 15 negative and 4 flats
• 6/4 – Wednesday closed positive with 18 positive, 13 negative and 4 flats
• 6/3 - Tuesday closed positive with 24 positive, 8 negative and 3 flats
• 6/2 - Monday closed positive with 25 positive, 7 negative and 3 flats

For the year:

• The S&P 500 is up 95.34 points, or 1.6%.
• The Dow is down 346.43 points, or 0.8%.
• The Nasdaq is up 96.03 points, or 0.5%.
• The Russell 2000 is down 129.65 points, or 5.8%.

Reiterating, “There are always some big ifs, especially given some of the headlines that could emanate after a past few months of news flatulence.

• Still a believer after I wrote, about June… “Get back-in and re-test the sector waters after May’s cell and gene therapy sector ‘s month alternations, nibble!  Some believe in a “June Swoon;” however, June will be no better or worse than any other month. Although, I consider the so-called summer rally after the peripatetic or wandering.”

As always, brace ourself for more volatility, economics and their down trending affect?

Welcome to my world of defining the “grey’ in our universe!

• The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
• I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.